UCB
Research UCB (UCB.BR) on Bullrun: market cap EUR 38.80B, P/E 18.0, dividend yield 0.7%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerUCB.BR
- ExchangeXBRU
- CountryBelgium
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 38.80B
- P/E18.0
- Dividend yield0.7%
- Financial periodFY2025
- RevenueEUR 7.74B
- Revenue growth25.8%
- Net incomeEUR 1.56B
- Free cash flowEUR 1.84B
- Gross margin74.3%
Valuation Snapshot
latest market cap is EUR 38.80B; P/E is 18.0; dividend yield is 0.7%.
Peer valuation comparison
Latest P/E is 17.98x versus a Healthcare sector median of 24.61x (26.9% below).
Latest dividend yield is 0.73% versus a Healthcare sector median of 1.84% (60.3% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 7.74B | EUR 1.56B | EUR 1.84B | 74.3% | 8.03 | EUR 2.25B | EUR 2.25B | EUR 10.87B |
| FY2024 | EUR 6.15B | EUR 1.07B | EUR 920.00M | 71.5% | n/a | EUR 1.57B | EUR 3.03B | EUR 10.03B |
| FY2023 | EUR 5.25B | EUR 343.00M | EUR 445.00M | 67.5% | 1.76 | EUR 861.00M | EUR 3.04B | EUR 8.98B |
| FY2022 | EUR 5.52B | EUR 418.00M | EUR 748.00M | 69.6% | 2.14 | EUR 899.00M | EUR 2.90B | EUR 9.06B |
| FY2021 | n/a | n/a | n/a | n/a | 5.45 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-11 | EUR 38.80B | 18.0 | 0.7% | 1.45 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.45 EUR, yield 0.7%.
| Year | Dividends/share |
|---|---|
| FY2025 | 1.39 EUR |
| FY2024 | 1.36 EUR |
| FY2023 | 1.33 EUR |
| FY2022 | 1.3 EUR |
| FY2021 | 1.27 EUR |
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is UCB's market cap?
UCB's market capitalization is EUR 38.80B.
What is UCB's P/E ratio?
UCB's price-to-earnings (P/E) ratio is 18.0.
Does UCB pay a dividend?
UCB has a dividend yield of 0.7%.
What does UCB do?
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome.